| abstract |
The invention is directed to the use of particular human genes, nucleic acids hybridizing to said genes, and gene products encoded thereby in the context of the diagnosis and/or therapy of metabolic and/or cancerous diseases, preferably of diabetes mellitus and/or colorectal cancer, wherein the gene is selected from the group of the human chromosomal genes having at least one expression regulatory sequence according to matrix 1 ("de novo" HNF4α matrix) in the range of 100000 nucleotides upstream or downstream of their transcription start site in the human genome, and wherein the at least one expression regulatory sequence according to matrix 1 is located within the chromosomal position specified by particular start and end sites. The invention further relates to a method for a genomewide identification of functional binding sites at specifically targeted DNA sequences with high resolution, wherein the method comprises, or preferably consists of, the steps of: a) chromatin immunoprecipitation and b) DNA-DNA hybridisation for the c) de n novo identification of gene targets. |